Previous administration of recombinant or wild type Lactococcus lactis NCDO2118 prevented severe mucositis in mice
Immunology Letters · 2026-10 · 281 · 107185
DOI: 10.1016/j.imlet.2026.107185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Letters, 2026-10. Verfasst von Patricia Aparecida Vieira de Barros und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais,…. Hauptthemen laut MEDLINE: Lactococcus lactis, Probiotics, Chaperonin 60, Mucositis. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Universidade Federal de Minas Gerais Pro-Reitoria de Pesquisa, CAPES.
Abstract (Originalsprache)
Mucositis is an inflammatory ulcerative condition that affects the mucous membranes of the entire gastrointestinal tract caused by anti-cancer chemotherapy. In the search for strategies to prevent or control this condition,many probiotic bacteria have been described as promising therapeutic tools. However, giving live bacteria during gut inflammatory conditions is a clinical concern and preventive treatments are the most suitable design namely when the disease onset is known as in the case of chemotherapy-induced mucositis. In the present study, we tested the effects of Lactococcus lactis NCDO2118 and Hsp65-producing L. lactis as a previous treatment to modulate intestinal mucosa immunity and prevent mucositis. Bacteria were given orally in a water bottle for four days. After ten days of the last treatment day, mucositis was induced. The results showed that pretreatment with either recombinant Hsp65-producing or wild type L. lactis NCDO2118 reduced intestinal permeability, preserved proteins of the junctional complex, and consequently controlled bacteria translocation. Pretreatment prevented the augment of inflammatory cells involved in mucositis pathogenesis, showing reduction in inflammation mediated by a favorable balance between cytokines. Furthermore, treatment of mice with recombinant or wild type L. lactis for four days modulated the gut microbiota contributing to intestinal homeostasis and to mucositis prevention. Together, our data showed that Hsp65-producing L. lactis and wild type L. lactis administered 10 days before disease induction had long-lasting immunoregulatory effects on mucositis. It provides an alternative therapeutic tool for mucositis that would avoid the risk of administering live bacteria during intestinal inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Odontologia Restauradora, Faculdade de Odontologia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Genética, Ecologia, Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
- Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; Instituto Nacional de Ciência e Tecnologia de Mucosas e Pele…
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Universidade Federal de Minas Gerais Pro-Reitoria de Pesquisa
- CAPES
- CNPq
Zitieren
APA
de Barros, P. A. V., Pinheiro-Rosa, N., Miranda, M. C. G., Alves, J. L., Espaladori, M. C., Assis, H. C., Júnior, R. E. M., Pessoa, R. M., Veloso, E. S., Vieira, A. T., Brunialti-Godard, A. L., Cardoso, V. N., Ferreira, E., Azevedo, V. A. C., Maioli, T. U., & Faria, A. M. C. (2026). Previous administration of recombinant or wild type Lactococcus lactis NCDO2118 prevented severe mucositis in mice. Immunology Letters, 281, 107185. https://doi.org/10.1016/j.imlet.2026.107185
Vancouver
de Barros PAV, Pinheiro-Rosa N, Miranda MCG, Alves JL, Espaladori MC, Assis HC, et al. Previous administration of recombinant or wild type Lactococcus lactis NCDO2118 prevented severe mucositis in mice. Immunology Letters. 2026;281:107185. doi:10.1016/j.imlet.2026.107185
BibTeX
@article{deBarros2026,
author = {de Barros, Patricia Aparecida Vieira and Pinheiro-Rosa, Natália and Miranda, Mariana Camila Goncalves and Alves, Juliana Lima and Espaladori, Marcela Carvalho and Assis, Helder Carvalho and Júnior, Renato Elias Moreira and Pessoa, Rafaela Miranda and Veloso, Emerson Soares and Vieira, Angélica Thomaz and Brunialti-Godard, Ana Lucia and Cardoso, Valbert Nascimento and Ferreira, Enio and Azevedo, Vasco Ariston Carvalho and Maioli, Tatiani Uceli and Faria, Ana Maria Caetano},
title = {Previous administration of recombinant or wild type Lactococcus lactis NCDO2118 prevented severe mucositis in mice},
journal = {Immunology Letters},
year = {2026},
volume = {281},
pages = {107185},
doi = {10.1016/j.imlet.2026.107185}
}
EUVIMED